Qiagen N.V. (NYSE:QGEN) Given Average Rating of “Hold” by Brokerages

Qiagen N.V. (NYSE:QGEN) has earned an average recommendation of “Hold” from the thirteen ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $43.1455.

A number of analysts recently commented on the stock. Wall Street Zen cut shares of Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings lowered shares of Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 29th. Zacks Research raised shares of Qiagen from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 29th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $43.00 price objective on shares of Qiagen in a research note on Thursday, April 30th. Finally, Kepler Capital Markets set a $38.60 target price on Qiagen and gave the company a “hold” rating in a research report on Thursday, June 25th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of QGEN. Allworth Financial LP raised its stake in shares of Qiagen by 23.2% in the third quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock worth $61,000 after purchasing an additional 256 shares during the last quarter. Banque Cantonale Vaudoise boosted its position in Qiagen by 1.8% in the fourth quarter. Banque Cantonale Vaudoise now owns 16,363 shares of the company’s stock valued at $747,000 after buying an additional 290 shares during the last quarter. Commerce Bank increased its holdings in Qiagen by 4.9% in the 4th quarter. Commerce Bank now owns 6,725 shares of the company’s stock worth $302,000 after buying an additional 314 shares during the period. Truist Financial Corp increased its holdings in Qiagen by 4.1% in the 4th quarter. Truist Financial Corp now owns 8,421 shares of the company’s stock worth $379,000 after buying an additional 331 shares during the period. Finally, Private Advisor Group LLC raised its position in Qiagen by 7.1% during the 3rd quarter. Private Advisor Group LLC now owns 5,730 shares of the company’s stock worth $256,000 after buying an additional 378 shares during the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Trading Up 0.0%

Qiagen stock opened at $41.52 on Monday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.57 and a current ratio of 3.21. The stock has a market cap of $8.56 billion, a PE ratio of 21.68, a price-to-earnings-growth ratio of 4.14 and a beta of 0.64. The stock has a 50-day moving average of $36.59 and a two-hundred day moving average of $42.56. Qiagen has a one year low of $32.53 and a one year high of $57.81.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.54 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.54. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.The business had revenue of $492.32 million for the quarter, compared to analyst estimates of $496.15 million. During the same quarter in the previous year, the firm earned $0.56 earnings per share. On average, research analysts anticipate that Qiagen will post 2.43 EPS for the current fiscal year.

Qiagen Increases Dividend

The company also recently declared an annual dividend, which will be paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th will be given a dividend of $0.35 per share. The ex-dividend date of this dividend is Tuesday, July 7th. This represents a yield of 90.0%. This is an increase from Qiagen’s previous annual dividend of $0.26. Qiagen’s payout ratio is presently 18.32%.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.